Francis Vanderbist

1.9k total citations
48 papers, 1.5k citations indexed

About

Francis Vanderbist is a scholar working on Pulmonary and Respiratory Medicine, Pharmaceutical Science and Physiology. According to data from OpenAlex, Francis Vanderbist has authored 48 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Pulmonary and Respiratory Medicine, 12 papers in Pharmaceutical Science and 10 papers in Physiology. Recurrent topics in Francis Vanderbist's work include Inhalation and Respiratory Drug Delivery (23 papers), Cystic Fibrosis Research Advances (12 papers) and Drug Solubulity and Delivery Systems (8 papers). Francis Vanderbist is often cited by papers focused on Inhalation and Respiratory Drug Delivery (23 papers), Cystic Fibrosis Research Advances (12 papers) and Drug Solubulity and Delivery Systems (8 papers). Francis Vanderbist collaborates with scholars based in Belgium, France and United Kingdom. Francis Vanderbist's co-authors include Karim Amighi, Gabrielle Pilcer, Jonathan Goole, Hamidou Traore, Thami Sebti, Marie Tré‐Hardy, Michel Devleeschouwer, Bruno Streel, Rita Vanbever and Véronique Préat and has published in prestigious journals such as Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy and European Respiratory Journal.

In The Last Decade

Francis Vanderbist

48 papers receiving 1.4k citations

Peers

Countries citing papers authored by Francis Vanderbist

Since Specialization

Citations

This map shows the geographic impact of Francis Vanderbist's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francis Vanderbist with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francis Vanderbist more than expected).

Fields of papers citing papers by Francis Vanderbist

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francis Vanderbist. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francis Vanderbist. The network helps show where Francis Vanderbist may publish in the future.

Co-authorship network of co-authors of Francis Vanderbist

This figure shows the co-authorship network connecting the top 25 collaborators of Francis Vanderbist. A scholar is included among the top collaborators of Francis Vanderbist based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francis Vanderbist. Francis Vanderbist is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Acquired resistance to macrolides inPseudomonas aeruginosafrom cystic fibrosis patients 2017 ·European Respiratory Journal ·(unknown), (unknown), Michael M. Tunney, J.S. Elborn, Barbara C. Kahl, Olivier Denis, Patrick Plésiat, Hamidou Traore, Paul M. Tulkens, Francis Vanderbist, Françoise Van Bambeke	38
2	Budesonide/salmeterol in fixed-dose combination for the treatment of asthma 2015 ·Expert Review of Respiratory Medicine ·Todor A. Popov, (unknown), Francis Vanderbist	2
3	New Co-Spray-Dried Tobramycin Nanoparticles-Clarithromycin Inhaled Powder Systems for Lung Infection Therapy in Cystic Fibrosis Patients 2013 ·Journal of Pharmaceutical Sciences ·Gabrielle Pilcer, Rémi Rosière, Karl Traina, Thami Sebti, Francis Vanderbist, Karim Amighi	38
4	Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis 2013 ·International Journal of Pharmaceutics ·Gabrielle Pilcer, (unknown), Karl Traina, Hamidou Traore, Thami Sebti, Francis Vanderbist, Karim Amighi	27
5	Safety of a Fixed-Dose Combination of Fenofibrate/Pravastatin 160 mg/40 mg in Patients with Mixed Hyperlipidaemia 2012 ·Clinical Drug Investigation ·Michel Farnier, (unknown), (unknown), Jean Ducobu, Armin Steinmetz, Kjetil Retterstøl, Leszek Bryniarski, Albert Császár, Francis Vanderbist	8
6	In vitro and in vivo evaluation of a dry powder endotracheal insufflator device for use in dose-dependent preclinical studies in mice 2012 ·European Journal of Pharmaceutics and Biopharmaceutics ·Christophe Duret, Nathalie Wauthoz, (unknown), Jonathan Goole, Calliope Maris, Isabelle Roland, Thami Sebti, Francis Vanderbist, Karim Amighi	41
7	Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa 2009 ·International Journal of Antimicrobial Agents ·Marie Tré‐Hardy, Hamidou Traore, (unknown), Francis Vanderbist, Mario Vaneechoutte, Michel Devleeschouwer	19
8	Significance of the biopharmaceutical properties of tramadol sustained-release formulations for chrono-pharmacologically optimized treatment of pain from various sources 2009 ·International Journal of Clinical Pharmacology and Therapeutics ·(unknown), Barbara Schug, Francis Vanderbist, (unknown)	3
9	Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates: the importance of the biofilm model 2008 ·International Journal of Antimicrobial Agents ·Marie Tré‐Hardy, Camille Macé, (unknown), Francis Vanderbist, Hamidou Traore, Michel Devleeschouwer	42
10	In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures 2008 ·International Journal of Antimicrobial Agents ·Marie Tré‐Hardy, Francis Vanderbist, Hamidou Traore, Michel Devleeschouwer	79
11	Pharmacoscintigraphic and pharmacokinetic evaluation on healthy human volunteers of sustained-release floating minitablets containing levodopa and carbidopa 2008 ·International Journal of Pharmaceutics ·Jonathan Goole, (unknown), Gabrielle Pilcer, (unknown), Didier Blocklet, Serge Goldman, Massimo Pandolfo, Francis Vanderbist, Karim Amighi	17
12	Pharmacoscintigraphic and pharmacokinetic evaluation of tobramycin DPI formulations in cystic fibrosis patients 2007 ·European Journal of Pharmaceutics and Biopharmaceutics ·Gabrielle Pilcer, Jonathan Goole, (unknown), Didier Blocklet, Christiane Knoop, Francis Vanderbist, Karim Amighi	27
13	Long-term tolerability of tramadol LP, a new once-daily formulation, in patients with osteoarthritis or low back pain 2005 ·Journal of Clinical Pharmacy and Therapeutics ·Hugues Malonne, M. Coffiner, Deborah Fontaine, (unknown), (unknown), Anne Peretz, Francis Vanderbist	32
14	Efficacy and tolerability of sustained-release tramadolin the treatment of symptomatic osteoarthritis of the hip or knee: A multicenter, randomized, double-blind, placebo-controlled study 2004 ·Clinical Therapeutics ·Hugues Malonne, M. Coffiner, (unknown), (unknown), Francis Vanderbist	60
15	Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1–34) from rat lungs 2004 ·Journal of Pharmaceutical Sciences ·(unknown), Francis Vanderbist, Bernard Učakar, Véronique Préat, Rita Vanbever	76
16	Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats 2003 ·Journal of Pharmaceutical Sciences ·(unknown), Francis Vanderbist, Roger K. Verbeeck, Mohammed Arras, Dominique Lison, Véronique Préat, Rita Vanbever	87
17	Deposition and pharmacokinetics of budesonide from the Miat Monodose inhaler, a simple dry powder device 2002 ·International Journal of Pharmaceutics ·(unknown), Peter H. Hirst, Stephen P. Newman, (unknown), Bruno Streel, Francis Vanderbist	22
18	Deposition of Nacystelyn from a Dry Powder Inhaler in Healthy Volunteers and Cystic Fibrosis Patients 2001 ·Drug Development and Industrial Pharmacy ·Francis Vanderbist, (unknown), Dana Baran, (unknown), André Schoutens, André Jules Moes	8
19	Enantiomeric determination of tramadol and its main metabolite O-desmethyltramadol in human plasma by liquid chromatography–tandem mass spectrometry 2000 ·Journal of Chromatography B Biomedical Sciences and Applications ·Attilio Ceccato, Francis Vanderbist, (unknown), Bruno Streel	70
20	Effect of the Mucoactive Drug Nacystelyn on the Respiratory Burst of Human Blood Polymorphonuclear Neutrophils 1997 ·Pulmonary Pharmacology & Therapeutics ·(unknown), Francis Vanderbist, (unknown), Pierrette Mäes, Pierre Fondu, Jan‐Walter De Neve	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact